- Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
- Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
- Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
- Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
- Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
- Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
- Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
- Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
- Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
- Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
More ▼
Key statistics
On Wednesday, Foghorn Therapeutics Inc. (FHTX:NMQ) closed at 5.62, 108.15% above the 52 week low of 2.70 set on Feb 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.48 |
---|---|
High | 5.79 |
Low | 5.34 |
Bid | 5.48 |
Offer | 6.19 |
Previous close | 5.44 |
Average volume | 178.42k |
---|---|
Shares outstanding | 55.33m |
Free float | 44.77m |
P/E (TTM) | -- |
Market cap | 310.95m USD |
EPS (TTM) | -2.21 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼